Prulifloxacin
As of the edition of 20 October 2026, Prulifloxacin is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Chinoplus
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Viatris Healthcare Lda.; 3 holders in all
- Registered trials
- 6, 0 stopped early
- Disease areas
- Digestive system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 3 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2006 to now |
| Lee's Pharmaceutical | Lead sponsor of trials | 2013 to now |
| Aziende Chimiche Riunite Angelini Francesco | Lead sponsor of trials | 2016 to now |